Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors

OBJECTIVES:

- Define the prevalence of audiometrically detectable hearing loss in patients with solid
tumors treated with oxaliplatin.

- Describe the association of chemotherapy-induced peripheral neuropathy (CIPN) and
audiometrically detectable hearing loss in these patients.

- Describe the association of CIPN and patient self-reported scales including, Peripheral
Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap
Inventory.

OUTLINE: This is an exploratory study.

Patients will complete three self-reported questionnaires including the Peripheral
Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory.
Patients will also be asked a series of questions regarding symptoms or complaints about
hearing changes, tinnitus, and dizziness that they may have experienced prior to, during,
and after completion of chemotherapy. Patients will also undergo a hearing test.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

- Diagnosis of solid tumor

- Received an oxaliplatin-containing chemotherapy regimen within the past 15
months* NOTE: *If oxaliplatin was omitted from the patient's most recent
chemotherapy regimen due to ototoxicity, the patient is still eligible for
participation in this study

- No known CNS metastases

PATIENT CHARACTERISTICS:

- No history of spinal injuries

- ECOG performance status 0-3

- No history of chronic renal failure

- No known HIV/AIDS

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics